Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval
Gossamer Bio, Inc. Common Stock · Now $0.20
+9.5% in 7d after detection
Post-detection moves
1h
—
1d
+3.3%
3d
+4.3%
7d
+9.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS